[1]
McMillan H.J., Kang P.B., Jones H.R., et al.: Childhood chronic inflammatory
demyelinating polyradiculoneuropathy: combined analysis of
a large cohort and eleven published series. Neuromuscul Disord 2013;
23: 103–111.
[2]
Rossignol E., D’Anjou G., Lapointe N., et al.: Evolution and treatment
of childhood chronic inflammatory polyneuropathy. Pediatr Neurol 2007;
36: 88–94.
[3]
European Federation of Neurological Societies/Peripheral Nerve Society
Guideline on management of paraproteinemic demyelinating neuropathies.
Report of a Joint Task Force of the European Federation of Neurological
Societies and the Peripheral Nerve Society-first revision. J Peripher
Nerv Syst 2010; 15: 185–195.
[4]
Kuitwaard K., van Doorn P.A.: Newer therapeutic options for chronic
inflammatory demyelinating polyradiculoneuropathy. Drugs 2009; 69:
987–1001.
[5]
Nobile-Orazio E., Cocito D., Jann S., et al.: Frequency and time to relapse
after discontinuing 6-month therapy with IVIg or pulsed methylprednisolone
in CIDP. J Neurol Neurosurg Psychiatry 2015; 86: 729–734.
[6]
van Schaik I.N., Eftimov F., van Doorn P.A. et al.: Pulsed high-dose dexamethasone
versus standard prednisolone treatment for chronic inflammatory
demyelinating polyradiculoneuropathy (PREDICT study): a double-
blind, randomised, controlled trial. Lancet Neurol 2010; 9: 245–253.
[7]
Desai J., Ramos-Platt L., Mitchell W.G.: Treatment of pediatric chronic
inflammatory demyelinating polyneuropathy: Challenges, controversies
and questions. Ann Indian Acad Neurol 2015; 18: 327–330.
[8]
Sladky J.T.: What is the best initial treatment for childhood chronic inflammatory
demyelinating polyneuropathy: corticosteroids or intravenous
immunoglobulin? Muscle Nerve 2008; 38: 1638–1643.
[9]
Berger M., Allen J.A.: Optimizing IgG therapy in chronic autoimmune
neuropathies: a hypothesis driven approach. Muscle Nerve 2015; 51:
315–326.
[10]
RMC Trial Group.: Randomised controlled trial of methotrexate for chronic
inflammatory demyelinating polyradiculoneuropathy (RMC trial):
a pilot, multicentre study. Lancet Neurol 2009; 8: 158–164.
[11]
Ripellino P., Fleetwood T., Cantello R. et al: Treatment of chronic inflammatory
demyelinating polyneuropathy: from molecular bases to practical
considerations. Autoimmune Dis 2014; 2014: 201657.
[12]
Dacci P., Riva N., Scarlato M., et al.: Subcutaneous immunoglobulin therapy
for the treatment of multifocal motor neuropathy: a case report.
Neurol Sci 2010; 31: 829–831.
[13]
Debs R., Reach P., Cret C., et al.: A new treatment regimen with highdose
and fractioned immunoglobulin in a special subgroup of severe and
dependent CIDP patients. Int J Neurosci 2017; 127: 864–872.
[14]
Fokkink W., Koch B., Ramakers C., et al.: Pharmacokinetics and Pharmacodynamics
of Intravenous Immunoglobulin G Maintenance Therapy in
Chronic Immune-mediated Neuropathies. Clin Pharmacol Ther 2017; doi:
10.1002/cpt.693. [Epub ahead of print].
Scholar Google
PubMed